AC Immune secures USD 4 million grant to advance its Parkinson’s immunotherapy

AC Immune will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial of ACI-7104, its immunotherapy for early Parkinson’s disease.

AC Immune, a clinical-stage biopharmaceutical company based in Lausanne, will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The grant will support the extension of Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, the company’s anti-alpha-synuclein active immunotherapy for early Parkinson’s disease.

The planned extension will assess the long-term safety and efficacy of ACI-7104 over an additional two years, generating data that is particularly valuable for patients with prodromal and early Parkinson’s disease, who are likely to require prolonged treatment. Final data from Part 1 of the trial are expected in the second half of 2026.

ACI-7104 is designed to generate a targeted antibody response against pathological forms of alpha-synuclein, a protein whose accumulation is known to contribute to the degeneration of neurons in Parkinson’s disease. Positive interim results reported in December 2025 suggested that targeting alpha-synuclein pathology could have a disease-modifying effect and slow disease progression, alongside a favorable safety profile and evidence of target engagement.

Founded and headquartered in Lausanne, AC Immune is a global leader in precision therapeutics for neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Its two clinically validated platforms, SupraAntigen and Morphomer, support a pipeline that has secured strategic partnerships with major pharmaceutical companies and more than USD 4.5 billion in potential milestone payments.